The Osteoarthritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032.
It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Osteoarthritis: An Overview
Osteoarthritis is a type of arthritis caused by inflammation, breakdown, and eventual loss of cartilage in the joints. Osteoarthritis (OA) is endemic throughout the world. An estimated 30.8 million adults in the United States and 300 million individuals worldwide are living with OA.
There is no medication to stop osteoarthritis (disease-modifying medication). The goal of treatment in osteoarthritis is to reduce joint pain and inflammation while improving and maintaining joint function. Duloxetine (Cymbalta) is FDA-approved for the treatment of chronic musculoskeletal pain. This includes osteoarthritis.
There are various drugs currently being studied for the treatment of Osteoarthritis. The Key players are Bone Therapeutics, Sorrento Therapeutics, Biosplice Therapeutics, Techfields Pharma, Eupraxia Pharmaceuticals, Novartis Pharmaceuticals, and others.
Osteoarthritis Market Key Facts
According to the EULAR Study Group (2015), it was estimated that OA affects about 40 million people in Europe. It was relatively infrequent in people under the age of 40 years but increased definitely with age. Under the age of 45 women were less affected than males which reverse above the age of 45.
Osteoarthritis (OA) is the 4th leading cause of disability across the world and is thought to be the most prevalent of all musculoskeletal pathologies, affecting an estimated 10% of the world’s population over the age of 60.
According to Osteoarthritis Action Alliance, while there are estimated to be more than 100 types of arthritis, OA is the most common form of arthritis, affecting 32.5 million US adults. 43% of people with OA are 65 or older and 88% of people with OA are 45 or older. 62% of individuals with OA are women. Among people younger than 45, OA is more common among men; above age 45, OA is more common among women.
Key Benefits of Osteoarthritis Market Report
The report provides an in-depth analysis of Osteoarthritis Market Size and Share till 2032 in the 7MM.
The report will help in developing business strategies by understanding the Osteoarthritis Market Trends, key players, and ongoing developments activities, that shape and drive the market growth in the upcoming years.
It covers Osteoarthritis’s current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.
The report provides a detailed assessment of the Osteoarthritis market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Osteoarthritis Market Size is anticipated to increase during the forecast period owing to the rising cases of Osteoarthritis in the 7MM. Increased prevalence, better disease understanding along with the emerging therapies, are also projected to boost the therapeutic market.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Osteoarthritis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Osteoarthritis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/osteoarthritis-market
The epidemiology section covers insights into the historical and current Osteoarthritis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Osteoarthritis Epidemiology Segmentation
Total prevalent cases of Osteoarthritis
Age-specific cases of Osteoarthritis
Gender-specific cases of Osteoarthritis
Diagnosed and Treatable cases of Osteoarthritis
Osteoarthritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Osteoarthritis market or expected to get launched in the market during the study period. The analysis covers Osteoarthritis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Osteoarthritis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Osteoarthritis Treatment can be broadly classified into the reduction of modifiable risk factors, intraarticular therapy, physical modalities, alternative therapies, and surgical treatments. NSAIDs and acetaminophen are generally considered first-line therapies in the treatment of Osteoarthritis. Other treatments include serotonin-norepinephrine reuptake inhibitors.
Recent evidence has implicated central sensitization as an important factor in pain in Osteoarthritis. The use of stronger medications, such as weak opioids and narcotic analgesics, can be considered when other medications have failed or are contraindicated.
Currently, several key companies are actively involved in the development of new therapies for the treatment of Osteoarthritis. The launch of the emerging therapies is expected to transform the treatment dynamics.
Some of the key companies in the Osteoarthritis Market include:
Jiangsu Carephar Pharmaceutical
And many others
Osteoarthritis Therapies covered in the report include:
Canakinumab (ACZ885, Ilaris) and LNA043
And many more
The Osteoarthritis therapeutics market has a promising outlook with the emerging therapies, consisting of several Phase III and Phase II assets.
Get More Detailed Insights into the Emerging Therapies & Key Companies: https://www.delveinsight.com/sample-request/osteoarthritis-market
Table of Content
1. Key Insights
2. Executive Summary
3. Osteoarthritis Competitive Intelligence Analysis
4. Osteoarthritis Market Overview at a Glance
5. Osteoarthritis Disease Background and Overview
6. Osteoarthritis Patient Journey
7. Osteoarthritis Epidemiology and Patient Population
8. Osteoarthritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Osteoarthritis Unmet Needs
10. Key Endpoints of Osteoarthritis Treatment
11. Osteoarthritis Marketed Products
12. Osteoarthritis Emerging Therapies
13. Osteoarthritis Seven Major Market Analysis
14. Attribute Analysis
15. Osteoarthritis Market Outlook (7 major markets)
16. Osteoarthritis Access and Reimbursement Overview
17. KOL Views on the Osteoarthritis Market.
18. Osteoarthritis Market Drivers
19. Osteoarthritis Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/osteoarthritis-market
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States